HBM Holdings Limited (2142.HK) HKSE
10.32
-0.46(-4.27%)
Currency In HKD
- General
- Statistics
- Historical Data
- Profile
- Financials
HBM Holdings Limited
Address
Tower A, 12th Floor
Shanghai, 200032
China
Phone
86 21 5339 9123
Sector
Healthcare
Industry
Biotechnology
Employees
183
First IPO Date
December 10, 2020
Key Executives
| Name | Title | Pay | Year Born |
| Jingsong Wang | Founder, Chairman & Chief Executive Officer | 8.66M | 1965 |
| Yiping Rong | Chief Scientific Officer & Executive Director | 3.32M | 1977 |
| Ben Chih | Chief Scientific Officer of Neurosciences - Harbour BioMed US | 0 | N/A |
| C. Adam Zong | President | 0 | N/A |
| Ian Y. Liu | Senior Vice President & Global Head of Legal and Joint Company Secretary | 0 | N/A |
| Peter F. Moesta | Member of Scientific Advisory Board & Chief CMC Advisor | 0 | N/A |
| Raymond S. Zheng | Chief Business Officer | 0 | N/A |
| Steve Arkinstall DPhil | Chief Scientific Advisor | 0 | N/A |
| Xiaolu Tao | Chief Development Officer | 0 | 1975 |
| Michael D. Patten | Chief Strategy Officer & Head of Global Alliance | 0 | N/A |
| Youchen Chen | Vice President, Chief Financial Officer & Investor Relations | 0 | N/A |
Description
HBM Holdings Limited, a clinical-stage biopharmaceutical company, engages in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. It is developing Batoclimab (HBM9161), a human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor; Tanfanercept (HBM9036) to treat moderate to-severe dry eye disease; HBM7008, a bispecific antibody targeting tumor Associated antigen; and HBM4003, a human anti-CTLA-4 antibody against cytotoxic T-lymphocyte-associated antigen-4. The company is also developing HBM9022 for the treatment of SARS-COV-2; HBM9302 for the treatment of breast and gastric cancers; HBM7020 for the treatment of multiple myeloma; and HBM1007, HBM1029, HBM7015, HBM7008, and HBM1022 for the treatment of solid tumors. It operates in Mainland China, the United States, Europe, and internationally. The company has collaboration on antibody-drug conjugate projects with LegoChem Biosciences Inc. and Duality Biotherapeutics, Inc. HBM Holdings Limited was incorporated in 2016 and is based in Shanghai, the People's Republic of China.
